Injectable 5-MeO-DMT: Subcutaneous Protocols, the Leckie Protocol, and Safe Trauma Release

Injectable 5-MeO-DMT is the future of working with this modality. When people discuss 5-MeO-DMT, they usually imagine vaporising toad venom (Incilius alvarius) or synthetic freebase crystals. While inhaled routes hit hard and fast—often plunging a person from full baseline consciousness into complete ego dissolution in under 10 seconds—they aren’t always ideal for therapeutic depth.

At Shangriballa, we focus on a gentler, more controllable approach: using an injectable 5-MeO-DMT salt form (specifically 5-MeO-DMT Succinate) administered subcutaneously.

Using liquid formulations changes the dynamic entirely. By slowing down the onset and stretching out the curve, we unlock a richer, more accessible landscape for trauma release and central nervous system regulation.

What Is 5-MeO-DMT Succinate Used in Injectable 5-MeO-DMT?

To create a stable liquid for parenteral routes, 5-MeO-DMT must be bound to a salt, creating a water-soluble compound like 5-MeO-DMT Succinate.

Freebase 5-MeO-DMT isn’t water-soluble enough for injection and breaks down easily when exposed to air. The succinate salt provides precise, measurable dosing while remaining stable in solution. This precision lets practitioners tailor doses directly to an individual’s nervous system capacity.

Subcutaneous vs. Intramuscular Administration

Understanding administration routes helps clarify why speed matters during therapeutic work:

• Intramuscular (IM): Injectable 5-MeO-DMT. The compound is injected directly into deep muscle tissue (like the deltoid or glute). Blood flow in muscle is high, so absorption is relatively fast. Onset usually happens within 1 to 3 minutes, with peak effects lasting longer than vaporised sessions.
• Subcutaneous (SQ): Injectable 5-MeO-DMT. The compound is injected into the fatty layer just beneath the skin (often in the abdomen or upper arm). Because fat tissue has less microvascular blood flow than muscle, absorption is slower and smoother.

Shangriballa prefers the subcutaneous route for targeted trauma work. Instead of hitting a sharp peak, the experience unfolds gradually over 5 to 10 minutes. This gives the body time to adjust, preventing the sudden “rocket ship” blast-off that can trigger protective panic.

The Therapeutic Advantage: Working Within the Trauma Window using Injectable 5-MeO-DMT

Vaporised 5-MeO-DMT often propels participants into total whiteout or non-dual union so quickly that they skip past their somatic holding patterns. While beautiful, it can miss the core emotional material.

With injectable 5-MeO-DMT via subcutaneous delivery, we can dial in lower, sub-peak doses.

When participants stay aware in that somatic trauma state without being overwhelmed, true release happens:

• Titrated Depth: Participants can track their physical sensations in real time.
• Active Processing: The mind retains enough executive functioning to stay anchored alongside the facilitator.
• Somatic Discharge: Tremors, emotional releases, and vocalisations can happen organically without throwing the central nervous system into freeze or shock.

Neurodivergence and Nervous System Regulation

For neurodivergent individuals—especially those with ADHD or hyper-analytical, left-brain processing styles—traditional psychedelic onsets can be jarring.

An active mind often fights rapid loss of control, resulting in somatic bracing or acute panic.

Subcutaneous administration acts as a gentle ramp. The slower onset gives the central nervous system time to down-regulate, letting hyper-vigilant minds ease their grip naturally.

What Are Reactivations in 5-MeO-DMT and Injectable 5-MeO-DMT Work?

A reactivation (sometimes called a “re-entry” or “flashback”) happens when a person re-experiences the physical, perceptual, or emotional state of 5-MeO-DMT days, weeks, or even months after a session. This usually happens during the deepest part of sleep between 3-5 am. For most individuals, they are not disturbing and are seen as the integration process, often referred to as night school.

For a small number of individuals, the reactivations can be disturbing and uncomfortable. The disturbance is not always that of reliving a traumatic event but rather a disruption of sleeping patterns for extended periods of time. It is very important that each individual be properly screened and assessed by a trained facilitator. This is especially important for people who have PTSD, CPTSD or are neurodivergent.

Reactivations often happen when a high-dose experience overwhelms the nervous system before the body can process the material. The unintegrated energy resurfaces later during sleep, times of stress, or micro-shifts in awareness.

For those navigating PTSD or Complex PTSD (C-PTSD), reactivations can feel destabilising. Careful preparation and guidance are needed before and after taking 5 Meo-DMT. This is not to say that individuals with the condition will not have a good outcome from vaping alone, but dose and administration need to be planned carefully by a trauma-informed trained facilitator.

Injectable 5-MeO-DMT reduces reactivation risks by keeping sessions grounded. When the nervous system stays within its window of tolerance, the body integrates the experience during the session—rather than trying to digest unhandled trauma weeks later.

What Is the Leckie Protocol?

The Leckie Protocol is a structured dosing methodology developed to balance rapid breakthrough with sustained therapeutic engagement, designed by the Enfold Institute.

Rather than relying on a single, massive dose, the framework combines or sequences routes—often pairing vaporised or IM administration with lower, continuous delivery.

How the Leckie Protocol Works:

1. Pushes Past Mind-Chatter: A targeted dose moves hyper-analytical or ADHD minds past executive resistance without forcing a shutdown.
2. Extends the Plateau: Instead of a fast drop-off, it holds a steady, manageable plateau.
3. Long Tail End for Integration: The tail end of the experience unwinds slowly over 30 to 60 minutes.

That extended landing gives participants time to sit with emerging insights, regulate their breathing, and process emotional releases with their facilitator before returning to baseline.

Scientific Context & Clinical Research

While non-oral 5-MeO-DMT research is expanding rapidly, parenteral routes are gaining attention for their safety and control:

• Pharmacokinetics: Research shows 5-MeO-DMT acts primarily as a 5-HT1A and 5-HT2A serotonin receptor agonist.
• Dosage Precision: A study on 5-MeO-DMT Succinate synthesis (PMC7745443) highlights how salt formulations allow exact metering compared to vaporising freebase, making sessions more predictable and safe.
• Therapeutic Safety: Clinical reviews in journals like Frontiers in Psychiatry confirm that controlled parenteral dosing offers favourable safety profiles, giving researchers better control over session length and intensity.

Closing Thoughts

Psychedelic work isn’t about chasing the biggest blast-off; it’s about holding space for meaningful, lasting change.

By using subcutaneous injectable 5-MeO-DMT succinate, Shangriballa offers a gentler path forward—one where the nervous system stays supported, trauma releases safely, and integration begins long before the session ends.